Skip to main content

and
  1. Article

    Open Access

    Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action

    Individuals with obesity are at increased risk of develo** infectious diseases. Timely administration of an effective dose of an antimicrobial agent is paramount to safeguard optimal therapy. For this purpos...

    K. P. van Rhee, C. A. J. Knibbe, P. D. van der Linden in Clinical Pharmacokinetics (2024)

  2. Article

    Open Access

    The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients

    Anti-Xa peak level monitoring is recommended during LMWH treatment in renal impairment or obesity. The trough level has been proposed as marker for bleeding. We studied the influence of renal impairment and ob...

    L. Mast, M. Y. M. Peeters, M. Söhne in European Journal of Clinical Pharmacology (2023)

  3. No Access

    Article

    Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review

    Obesity and its related complications are increasing health issues. Since generally only minor weight loss is obtained with lifestyle intervention, additional pharmacological therapies such as metformin are of...

    Y. E. Lentferink, C. A. J. Knibbe, M. M. J. van der Vorst in Drugs (2018)

  4. No Access

    Article

    Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery

    Objective: A new formulation of propofol 6% in Lipofundin MCT/LCT 10% (propofol 6% SAZN) has been developed in order to reduce the fat, emulsifier and volume load that is given during pr...

    C. A. J. Knibbe, L. P. H. J. Aarts in European Journal of Clinical Pharmacology (2000)